Back to search results

TCR1188-ABC Cells for KRAS-mutated Cancers

This study is testing a new cell therapy called TCR1188-ABC cells for people with certain advanced cancers that have a specific genetic change called a KRAS mutation. These cancers include pancreatic, colorectal, non-small cell lung cancer, and cholangiocarcinoma (bile duct cancer). You would receive a single infusion of TCR1188-ABC cells, along with other medications like Fludarabine, Cyclophosphamide, and Tocilizumab. The main goals are to see how safe the treatment is, if it can be successfully made for each patient, and to find the best dose. Researchers will watch for side effects for up to 15 years. You must be at least 18 years old and have a specific genetic marker called HLA-A*11:01.

Study design
This is a Phase I, open-label study, meaning both you and the study team will know what treatment you are receiving. It aims to enroll 30 participants to find the right dose.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will monitor you for treatment-related side effects for up to 15 years after receiving the TCR1188-ABC cells.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07594067

TCR1188-ABC Cells in KRAS-mutated Cancers

Recruiting
PHASE1Ages 18+InterventionalTreatment
University of Pennsylvania
~30 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:TCR1188-ABC cellsFludarabine + Cyclophosphamide combinationTocilizumab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V6.0
Measured over Up to 15 years following TCR1188-ABC cell administration
+2 more outcomes measured

Conditions

Cholangiocarcinoma
Colorectal Cancer
Non-Small Cell Lung Cancer
Pancreatic Adenocarcinoma

Explore related trials

CholangiocarcinomaColorectal CarcinomaLung Non-Small Cell CarcinomaPancreatic AdenocarcinomaGTPase KRasHLA-A Gene

Where it's being run

1 sites across 1 states
Pennsylvania1

Who to contact

Abramson Cancer Center Clinical Trials Service
[email protected]
215-349-8245
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V6.0Up to 15 years following TCR1188-ABC cell administration

    Type, frequency, severity, and attribution of adverse events

  • Occurrence of dose-limiting toxicities (DLTs)Up to 28 days following TCR1188-ABC cell administration

    Type, frequency, severity, and attribution of dose limiting adverse events as defined by the protocol

  • Identification of the maximum tolerated dose (MTD)28 days post-TCR1188-ABC cell infusion

    The highest dose at which 0 or 1 DLT occurs in 6 DLT-evaluable subjects will be declared the MTD.